Navigation Links
Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
Date:6/7/2013

NEW YORK, June 7,­­­­ 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent issuance of 2,095,204 of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.  The warrants were exercised at US$ 1.65 per share, resulting in gross proceeds of US$ 3,457,087 for the Company.  As of June 7, 2013 the total number of outstanding common stock is 15,825,394 shares.

"The proceeds from these exercised warrants will be used for the Companies clinical and preclinical programs and for general working capital," said Sergio Traversa, Interim Chief Executive Officer of Actinium Pharmaceuticals.  "This capital will allow us to continue to develop our drug candidates for treatment of the most difficult forms of cancer, including Acute Myeloid Leukemia, where they have made significant advances and already helped a number of patients," added Dragan Cicic, MD, Chief Medical Officer of Actinium Pharmaceuticals.  "The Company intends to advance its programs into late phases of clinical trials and add new programs by the end of 2013."

Shareholders exercised 2,095,204 (67.2%) of the 3,118,988 originally issued A-warrants. 

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., based in New York, NY, is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or

Contact:
Segio Traversa, CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com


Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0150
E-mail: dsdobson@optonline.com
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
2. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
3. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
4. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
5. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
6. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
7. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
8. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
9. Actinium Pharmaceuticals Announces New Round of Financing
10. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
11. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
(Date:9/12/2017)... reviews on the independent review site Consumer Affairs have ... hearing aids, ranking it higher than Miracle Ear ™, Beltone™, ... ... Aids ... that provides high performance, state-of-the-art, German-engineered hearing aids directly to consumers ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids this ... by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited about ... ages; it is a non-competitive, non-timed event, which is all about having fun and ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
Breaking Medicine News(10 mins):